Provided by Tiger Trade Technology Pte. Ltd.

Merck

149.86
+2.101.42%
Pre-market: 150.390.5300+0.35%08:48 EDT
Volume:9.87M
Turnover:1.48B
Market Cap:369.73B
PE:117.74
High:151.68
Open:150.23
Low:148.55
Close:147.76
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.98
T/O Rate:0.40%
Dividend:3.32
Dividend Rate:2.22%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.82
PE(LYR):20.59

Loading ...

CICC Initiates Merck & Co. at Outperform With $138 Price Target

MT Newswires Live
·
Jun 24

Merck initiated with an Outperform at CICC

TIPRANKS
·
Jun 24

Movement Alert|Merck Rises 3.03% in Regular Trading, Multiple Catalysts Including Phase 3 Trial Success and Potential Major Acquisition

Market Focus
·
Jun 24

Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23

Citi Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23

Merck (MRK) Stock Could Be 11% Undervalued After June Pipeline Wins

Simply Wall St.
·
Jun 23

Spanish stocks - Factors to watch on June 23

Reuters
·
Jun 23

Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23

Merck & Co. Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 23

Merck's bowel disease drug meets main goal in late-stage trial

Reuters
·
Jun 22

Merck's Tulisokibart Hits Key Goals in Phase 3 Ulcerative Colitis Study

Dow Jones
·
Jun 22

Merck announces ‘positive’ results from Phase 3 trial of tulisokibart

TIPRANKS
·
Jun 22

Merck says Phase 3 trial shows tulisokibart meets primary endpoint in ulcerative colitis study

Reuters
·
Jun 22

Merck & Co - No Safety Concerns Identified in Phase 3 Atlas-Uc Study of Tulisokibart

THOMSON REUTERS
·
Jun 22

Merck & Co - Tulisokibart First Anti-Tl1a Antibody to Show Clinical Remission at 12 Weeks in Phase 3 Uc Trial

THOMSON REUTERS
·
Jun 22

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 Atlas-Uc Induction-Only Study in Patients With Moderately to Severely Active Ulcerative Colitis (Uc)

THOMSON REUTERS
·
Jun 22

Berenberg Adjusts Price Target on Merck & Co. to $125 From $115, Maintains Hold Rating

MT Newswires Live
·
Jun 22

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Reuters
·
Jun 22

This Investment Pro Is Leaning Into Risk -- Barron's

Dow Jones
·
Jun 20

Merck & Co. Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Jun 19